Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Zevra Therapeutics (ZVRA) Preferred Dividend Payments (2021)

Zevra Therapeutics (ZVRA) has disclosed Preferred Dividend Payments for 1 consecutive years, with $16.9 million as the latest value for Q2 2021.

  • For the quarter ending Q2 2021, Preferred Dividend Payments changed N/A year-over-year to $16.9 million, compared with a TTM value of $16.9 million through Mar 2022, changed N/A, and an annual FY2021 reading of $54.3 million, changed N/A over the prior year.
  • Preferred Dividend Payments was $16.9 million for Q2 2021 at Zevra Therapeutics, down from $37.4 million in the prior quarter.
  • Across five years, Preferred Dividend Payments topped out at $37.4 million in Q1 2021 and bottomed at $16.9 million in Q2 2021.